Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs

被引:83
作者
Bourgault, Steve [1 ,2 ,3 ]
Choi, Sungwook [1 ,2 ,3 ]
Buxbaum, Joel N. [1 ]
Kelly, Jeffery W. [1 ,2 ,3 ]
Price, Joshua L. [1 ,2 ,3 ]
Reixach, Natalia [1 ]
机构
[1] Scripps Res Inst, Dept Mol & Expt Med, MEM 230, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
基金
美国国家卫生研究院;
关键词
Protein misfolding; Amyloid; Transthyretin; Cytotoxicity; Resveratrol; Cardiomyopathy; ONSET CARDIAC AMYLOIDOSIS; FIBRIL INHIBITORS; DISEASE; BINDING; VARIANT; AMYLOIDOGENESIS; POLYNEUROPATHY; CYTOTOXICITY; AMERICANS; OLIGOMERS;
D O I
10.1016/j.bbrc.2011.04.133
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The transthyretin amyloidoses are a subset of protein misfolding diseases characterized by the extracellular deposition of aggregates derived from the plasma homotetrameric protein transthyretin (TTR) in peripheral nerves and the heart. We have established a robust disease-relevant human cardiac tissue culture system to explore the cytotoxic effects of amyloidogenic TTR variants. We have employed this cardiac amyloidosis tissue culture model to screen 23 resveratrol analogs as inhibitors of amyloidogenic TTR-induced cytotoxicity and to investigate their mechanisms of protection. Resveratrol and its analogs kinetically stabilize the native tetramer preventing the formation of cytotoxic species. In addition, we demonstrate that resveratrol can accelerate the formation of soluble non-toxic aggregates and that the resveratrol analogs tested can bring together monomeric TTR subunits to form non-toxic native tetrameric (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:707 / 713
页数:7
相关论文
共 37 条
[1]   Discovering transthyretin amyloid fibril inhibitors by limited screening [J].
Baures, PW ;
Peterson, SA ;
Kelly, JW .
BIOORGANIC & MEDICINAL CHEMISTRY, 1998, 6 (08) :1389-1401
[2]   Sulfated Glycosaminoglycans Accelerate Transthyretin Amyloidogenesis by Quaternary Structural Conversion [J].
Bourgault, Steve ;
Solomon, James P. ;
Reixach, Natalia ;
Kelly, Jeffery W. .
BIOCHEMISTRY, 2011, 50 (06) :1001-1015
[3]  
Buxbaum J. N, 2008, RHEUMATOLOGY, P1671
[4]   Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity [J].
Buxbaum, Joel N. ;
Ye, Zhengyi ;
Reixach, Natlia ;
Friske, Linsey ;
Levy, Coree ;
Das, Pritam ;
Golde, Todd ;
Masliah, Eliezer ;
Roberts, Amanda R. ;
Bartfai, Tamas .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (07) :2681-2686
[5]  
Buxbaum Joel N., 2004, Current Opinion in Rheumatology, V16, P67, DOI 10.1097/00002281-200401000-00013
[6]   Transthyretin: the servant of many masters [J].
Buxbaum, Joel N. ;
Reixach, Natalia .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2009, 66 (19) :3095-3101
[7]   A Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and Cytotoxicity [J].
Choi, Sungwook ;
Reixach, Natalia ;
Connelly, Stephen ;
Johnson, Steven M. ;
Wilson, Ian A. ;
Kelly, Jeffery W. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2010, 132 (04) :1359-1370
[8]  
Choi S, 2010, NAT CHEM BIOL, V6, P133, DOI [10.1038/NCHEMBIO.281, 10.1038/nchembio.281]
[9]  
Coelho Teresa, 1993, Journal of Rheumatology, V20, P179
[10]   Tabulation of human transthyretin (TTR) variants, 2003 [J].
Connors, LH ;
Lim, A ;
Prokaeva, T ;
Roskens, VA ;
Costello, CE .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2003, 10 (03) :160-184